Macrocyclic peptide AR-01 crosses blood-brain barrier, inhibits LMP2, and improves cognition in 5xFAD Alzheimer's mice

Alzheimer's disease (AD) remains a devastating neurodegenerative disorder with current treatments offering only symptomatic relief, failing to halt disease progression. A key pathological driver is chronic neuroinflammation, often mediated by activated microglia. The immunoproteasome, particularly its catalytic subunit LMP2 (low-molecular-mass polypeptide-2), plays a critical role in enhancing antigen presentation and regulating inflammatory responses. Targeting LMP2 offers a novel strategy to suppress microglia-mediated inflammation, addressing a significant gap in AD therapeutics beyond amyloid or tau pathology.

Researchers evaluated the pharmacokinetic properties of AR-01, an irreversible macrocyclic peptide epoxyketone, in healthy mice and rats, focusing on brain permeability (brain-to-plasma partition coefficient). They verified AR-01 target engagement in the brain using two methods: an LMP2 activity assay and Western blotting to detect the irreversible LMP2:AR-01 adduct. For efficacy, 5xFAD mice, a model of amyloidogenesis, received multiple doses of AR-01 to assess cumulative LMP2 adduct formation and subsequent improvements in cognitive function.

Pharmacokinetic analysis confirmed that AR-01 possesses favorable properties for crossing the blood-brain barrier, a significant hurdle for peptide-based CNS drugs. A single intravenous administration of AR-01 was shown to inactivate LMP2 in the mouse brain in a dose-dependent manner. This inactivation was verified by both the LMP2 activity assay and the characteristic LMP2 band shift observed on Western blotting, indicating irreversible adduct formation. Importantly, multiple doses of AR-01 led to cumulative LMP2 adduct formation within the mouse brain. This sustained target engagement translated into significant functional benefits:

AR-01 treatment improved cognitive function in 5xFAD mice, a widely recognized model of amyloidogenesis and AD-like pathology. These findings collectively suggest that AR-01 successfully reaches its target in the brain and exerts therapeutic effects.